H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $2.44.
According to TipRanks, Bodnar is an analyst with an average return of -18.1% and a 26.32% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Gracell Biotechnologies, NovoCure, and Agenus.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IO Biotech with a $8.33 average price target.
See Insiders’ Hot Stocks on TipRanks >>
IOBT market cap is currently $70.31M and has a P/E ratio of -0.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Read More on IOBT:
